ATE250593T1 - Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen - Google Patents

Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Info

Publication number
ATE250593T1
ATE250593T1 AT96942433T AT96942433T ATE250593T1 AT E250593 T1 ATE250593 T1 AT E250593T1 AT 96942433 T AT96942433 T AT 96942433T AT 96942433 T AT96942433 T AT 96942433T AT E250593 T1 ATE250593 T1 AT E250593T1
Authority
AT
Austria
Prior art keywords
taxal
derivatives
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT96942433T
Other languages
German (de)
English (en)
Inventor
Herve Bouchard
Alain Commercon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE250593T1 publication Critical patent/ATE250593T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96942433T 1995-12-22 1996-12-19 Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen ATE250593T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9515379A FR2742751B1 (fr) 1995-12-22 1995-12-22 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR1996/002031 WO1997023473A1 (fr) 1995-12-22 1996-12-19 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ATE250593T1 true ATE250593T1 (de) 2003-10-15

Family

ID=9485871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942433T ATE250593T1 (de) 1995-12-22 1996-12-19 Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Country Status (40)

Country Link
US (1) US5728849A (cg-RX-API-DMAC10.html)
EP (1) EP0876362B1 (cg-RX-API-DMAC10.html)
JP (1) JP3953106B2 (cg-RX-API-DMAC10.html)
KR (1) KR100500351B1 (cg-RX-API-DMAC10.html)
CN (1) CN1103766C (cg-RX-API-DMAC10.html)
AR (1) AR005197A1 (cg-RX-API-DMAC10.html)
AT (1) ATE250593T1 (cg-RX-API-DMAC10.html)
AU (1) AU712597B2 (cg-RX-API-DMAC10.html)
BG (1) BG63204B1 (cg-RX-API-DMAC10.html)
BR (1) BR9612135A (cg-RX-API-DMAC10.html)
CA (1) CA2238884C (cg-RX-API-DMAC10.html)
CO (1) CO4520184A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ294972B6 (cg-RX-API-DMAC10.html)
DE (1) DE69630145T2 (cg-RX-API-DMAC10.html)
DK (1) DK0876362T3 (cg-RX-API-DMAC10.html)
DZ (1) DZ2149A1 (cg-RX-API-DMAC10.html)
EA (1) EA001533B1 (cg-RX-API-DMAC10.html)
ES (1) ES2202490T3 (cg-RX-API-DMAC10.html)
FR (1) FR2742751B1 (cg-RX-API-DMAC10.html)
HU (1) HU225032B1 (cg-RX-API-DMAC10.html)
IL (1) IL124994A (cg-RX-API-DMAC10.html)
IN (4) IN186768B (cg-RX-API-DMAC10.html)
MA (1) MA26412A1 (cg-RX-API-DMAC10.html)
MX (1) MX9804688A (cg-RX-API-DMAC10.html)
MY (1) MY113934A (cg-RX-API-DMAC10.html)
NO (1) NO317358B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ324337A (cg-RX-API-DMAC10.html)
OA (1) OA10700A (cg-RX-API-DMAC10.html)
PE (1) PE25198A1 (cg-RX-API-DMAC10.html)
PL (1) PL189311B1 (cg-RX-API-DMAC10.html)
PT (1) PT876362E (cg-RX-API-DMAC10.html)
RO (1) RO116194B1 (cg-RX-API-DMAC10.html)
SK (1) SK282835B6 (cg-RX-API-DMAC10.html)
TN (1) TNSN96169A1 (cg-RX-API-DMAC10.html)
TR (1) TR199801179T2 (cg-RX-API-DMAC10.html)
TW (1) TW371659B (cg-RX-API-DMAC10.html)
UA (1) UA48205C2 (cg-RX-API-DMAC10.html)
UY (1) UY24386A1 (cg-RX-API-DMAC10.html)
WO (1) WO1997023473A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA9610737B (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
CZ20013405A3 (cs) 2000-02-02 2002-03-13 Florida State University Research Foundation, Inc. C10 karbonátem substituované taxany jako protinádorová činidla
SK286975B6 (sk) * 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080107721A1 (en) * 2003-05-20 2008-05-08 Jonathan Lewis Combination Chemotherapy Comprising A Liposomal Platinum Complex
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR101541791B1 (ko) * 2006-05-04 2015-08-04 베링거 인겔하임 인터내셔날 게엠베하 다형태
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2934843T3 (es) 2011-07-15 2023-02-27 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
FR3010839B1 (fr) * 2013-09-17 2017-04-21 Schneider Electric Ind Sas Dispositif de raccordement electrique d'au moins un conducteur dans une borne appartenant a un appareil electrique
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP4678240A2 (en) 2015-07-12 2026-01-14 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
MX2019005583A (es) 2016-11-14 2019-10-21 Hangzhou Dac Biotech Co Ltd Vinculantes de conjugacion, conjugados de molecula de union a celulas que contienen los vinculantes, metodos de creacion y usos de dichos conjugados con los vinculantes.
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017724C1 (ru) * 1990-07-12 1994-08-15 Дзе Юниверсити оф Канзас Способ получения производных таксола
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
AU672006B2 (en) * 1992-04-17 1996-09-19 Abbott Laboratories Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
MX9307777A (es) * 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.

Also Published As

Publication number Publication date
ES2202490T3 (es) 2004-04-01
EA001533B1 (ru) 2001-04-23
CA2238884C (fr) 2007-02-06
BR9612135A (pt) 1999-07-13
NO982580L (no) 1998-06-05
CA2238884A1 (fr) 1997-07-03
IN188680B (cg-RX-API-DMAC10.html) 2002-10-26
DE69630145D1 (de) 2003-10-30
IL124994A (en) 2000-12-06
IN188469B (cg-RX-API-DMAC10.html) 2002-09-28
BG63204B1 (bg) 2001-06-29
EP0876362A1 (fr) 1998-11-11
HUP9904046A1 (hu) 2001-04-28
NZ324337A (en) 2000-03-27
MA26412A1 (fr) 2004-12-20
AU712597B2 (en) 1999-11-11
AR005197A1 (es) 1999-04-14
NO982580D0 (no) 1998-06-05
PL327405A1 (en) 1998-12-07
FR2742751A1 (fr) 1997-06-27
SK85398A3 (en) 1998-11-04
TW371659B (en) 1999-10-11
MY113934A (en) 2002-06-29
BG102569A (en) 1999-04-30
KR19990076680A (ko) 1999-10-15
IN186768B (cg-RX-API-DMAC10.html) 2001-11-03
MX9804688A (es) 1998-10-31
ZA9610737B (en) 1997-06-27
DE69630145T2 (de) 2004-07-15
PE25198A1 (es) 1998-05-10
DK0876362T3 (da) 2004-02-02
UA48205C2 (uk) 2002-08-15
RO116194B1 (ro) 2000-11-30
OA10700A (fr) 2002-11-27
US5728849A (en) 1998-03-17
EP0876362B1 (fr) 2003-09-24
EA199800588A1 (ru) 1998-12-24
IL124994A0 (en) 1999-01-26
IN188470B (cg-RX-API-DMAC10.html) 2002-09-28
KR100500351B1 (ko) 2005-12-21
CZ294972B6 (cs) 2005-04-13
HK1017895A1 (en) 1999-12-03
NO317358B1 (no) 2004-10-18
TNSN96169A1 (fr) 2005-03-15
PL189311B1 (pl) 2005-07-29
HUP9904046A3 (en) 2001-08-28
PT876362E (pt) 2004-02-27
UY24386A1 (es) 2001-08-27
JP2000502671A (ja) 2000-03-07
WO1997023473A1 (fr) 1997-07-03
CN1103766C (zh) 2003-03-26
SK282835B6 (sk) 2002-12-03
HU225032B1 (en) 2006-05-29
CN1205697A (zh) 1999-01-20
DZ2149A1 (fr) 2002-10-23
JP3953106B2 (ja) 2007-08-08
FR2742751B1 (fr) 1998-01-30
CZ196198A3 (cs) 1998-09-16
TR199801179T2 (xx) 1998-10-21
CO4520184A1 (es) 1997-10-15
AU1180997A (en) 1997-07-17

Similar Documents

Publication Publication Date Title
ATE250593T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69606028D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
DE69131813D1 (de) Amido-3-Pyrazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
DE69928260D1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
FI934274A7 (fi) N-sulfonyyli-2-oksi-indolijohdannaiset, niiden valmistus ja niitä sisä ltävät farmaseuttiset koostumukset
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
DE69616323D1 (de) Aromatische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
ATE297935T1 (de) 2-(iminomethyl)aminophenyl-derivate, deren herstellung, verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
DE68920963D1 (de) Aralkylamin-Derivate, deren Herstellung und diese enthaltende fungizide Mittel.
FI953898A7 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
DE69608680D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69618210D1 (de) Aromatische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
ATE222897T1 (de) Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen,die sie enthalten
HUP9901096A3 (en) Indole derivatives, preparation and use thereof, pharmaceutical composition containing these compounds
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
DE59814412D1 (de) Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
ATE195940T1 (de) Taxol derivate,deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
FI943645A7 (fi) Uusia bakkatiini-III ja 10-deasetyylibakkatiini-III-johdannaisia, niid en valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
EE9800069A (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
HUP9900865A3 (en) Anti-viral benzimidazole derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds
ATE204266T1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69520870D1 (de) Esculetin Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0876362

Country of ref document: EP